Secukinumab-induced chronic discoid lupus erythematosus
Giannis Chatzimichail, Detlef Zillikens, Diamant Thaçi
Abstract
Drug-induced lupus erythematosus is a rare adverse event of biological treatment, mainly observed with tumor necrosis factor–α antagonists and also known as lupus-like syndrome. Recently, it was also described with interleukin (IL) 17 inhibition. Here, we report the case of a 39-year-old man with onset of cutaneous discoid lupus erythematosus during subcutaneous administration of the IL-17A inhibitor secukinumab, which was initiated for the treatment of chronic plaque psoriasis.
Topics & Concepts
MedicineSecukinumabDiscoid lupus erythematosusDermatologyLupus erythematosusAdverse effectSystemic lupus erythematosusCutaneous Lupus ErythematosusTumor necrosis factor alphaPsoriasisImmunologyInternal medicineAntibodyPsoriatic arthritisDiseasePsoriasis: Treatment and PathogenesisSystemic Lupus Erythematosus ResearchAutoimmune Bullous Skin Diseases